Key Stats for ISRG Stock
- 30-Day Performance: -9%
- 52-Week Range: $418 to $604
- Valuation Model Target Price: Around $625
- Implied Upside: Around 43%
Analyze your favorite stocks like Intuitive Surgical with TIKR (It’s free) >>>
What Happened?
Intuitive Surgical, Inc. stock fell about 9% over the last 30 days, recently trading near $438 per share as investors reassessed one of medtech’s highest-quality growth stories at a lower valuation. Intuitive is best known for da Vinci, its robotic-assisted surgery platform, while Ion gives the company a separate robotic lung biopsy business that helps doctors sample suspicious lung nodules.
The pullback came as investors compared Intuitive’s premium valuation with large medtech peers and adjacent competitors such as Medtronic, Stryker, Johnson & Johnson MedTech, Zimmer Biomet, and Abbott Laboratories, where growth is generally slower but valuations are often less demanding.
The stock moved lower because analyst target cuts made valuation the main story, even though Q1 results were strong. Bank of America kept its Buy rating but lowered its target from $650 to $520, while Leerink Partners, Piper Sandler, JPMorgan, TD Cowen, HSBC, and Barclays also recently reduced their targets. That mattered because ISRG was already priced like a best-in-class growth stock, so lower targets gave investors a reason to reset expectations and take a more cautious view of the stock’s premium multiple, even as da Vinci 5 adoption, procedure growth, and recurring revenue remained healthy.
The recent earnings call showed Intuitive delivered a strong Q1, with revenue rising 23% to $2.77 billion, total procedures up 17%, da Vinci procedures up 16% to 847,000, and Ion procedures up 39% to 43,000.
CEO David Rosa called Q1 a “solid start to the year,” supported by broad adoption across da Vinci and Ion, while the company placed 431 da Vinci systems, including 232 da Vinci 5 systems, and 52 Ion systems. Intuitive also raised its 2026 da Vinci procedure growth outlook to 13.5% to 15.5% and increased its non-GAAP gross margin outlook to 67.5% to 68.5%, even while factoring in 100 basis points of tariff impact.
Recent institutional filings added to the mixed story, with several firms adding exposure while others trimmed positions. Global Retirement Partners increased its Intuitive Surgical stake by 71% in the fourth quarter to 23,876 shares worth about $14 million, while PNC Financial Services increased its stake by 22% to 160,677 shares worth about $91 million.
At the same time, Verde Servicos Internacionais cut its stake by 51% to 16,446 shares, reinforcing the bigger debate around ISRG: the business still has strong 2026 drivers, but investors are staying selective because the valuation remains demanding.
Value Intuitive Surgical instantly (Free with TIKR) >>>
Is ISRG Undervalued?
Under valuation assumptions, the stock is modeled using:
- Revenue Growth: Around 14%
- Operating Margins: Around 39%
- Exit P/E Multiple: 41x
Revenue growth is being supported by higher da Vinci procedure volume, broader da Vinci 5 adoption, Ion growth in lung biopsy, and a larger installed base that creates more instruments, accessories, and service revenue.
That recurring revenue base matters because Intuitive can earn more as procedure volume rises, even without selling a new robotic system every time.
See analysts’ growth forecasts and price targets for Intuitive Surgical (It’s free) >>>
The next 12 months will likely come down to hospital adoption of da Vinci 5, new robotic surgery reimbursement in Japan starting in June 2026, and whether China’s tender and pricing pressure stays manageable.
Margins remain a key part of the setup because da Vinci 5 has reached contribution margins comparable with Xi, while Ion is now close to the corporate average, giving Intuitive more room to convert growth into earnings.
At current levels, Intuitive Surgical appears undervalued based on the model, with future performance likely driven by procedure growth, platform upgrades, recurring revenue expansion, and the market’s willingness to keep rewarding one of medtech’s strongest franchises.
How Much Upside Does ISRG Stock Have From Here?
Investors can estimate Intuitive Surgical’s potential share price, or what any stock could be worth, in under a minute using TIKR’s New Valuation Model tool.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
Value Intuitive Surgical in under 60 seconds with TIKR (It’s free) >>>
